The companies will create an assay to test the human liver toxicity of new drugs.
ReNeuron and CellSeed signed a collaboration agreement to develop liver-cell culture systems for drug safety screening in the pharmaceutical industry.
The development work, to be conducted in CellSeed’s laboratories in Tokyo, will establish protocols for developing ReNeuron’s ReNcell™ HEP hepatocyte cell-lines in combination with CellSeed’s UpCell and HydroCell temperature-sensitive polymer products for 3-D functional liver tissue.
3-D liver culture systems represent a way to assay for human liver toxicity of new drugs. The collaboration will enable the joint development of human cell-based drug discovery products for use in the pharmaceutical industry.
